Science and nature

Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian

Retrieved on: 
星期二, 四月 23, 2024
Nature Immunology, School, University, Cancer, Biogen, COVID, SAB, Remdesivir, Medical school, Merck & Co., Los Angeles School, Eli Lilly, Amgen, Developmental Biology (journal), Inflammation, STAT3, Molecular biology, Yale University, Research, Lupus, STAT6, Growth, SH2, JAMA, Eli Lilly and Company, UCSF, Patient, Doctor of Pharmacy, Rheumatoid arthritis, Psoriasis, Vasculitis, Morphic, Lilly, Multiple sclerosis, Drug discovery, SAN, Division, Investigational New Drug, Science and nature, Pharmaceutical industry

“We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix. “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development. He has extensive expertise in immunology and has led the advancement and strategic oversight of deep pipelines with more than ten product candidates reaching the clinic during his Lilly tenure. At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6. Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets. Ajay’s deep experience leading a broad discovery and development immunology portfolio – both internally and through strategic partnerships -- is ideally suited to capitalize on the many opportunities at Recludix.”

Key Points: 
  • “We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix.
  • “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development.
  • At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6.
  • Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets.

Inflammasome Therapeutics Announces First Patient Dosed in Geographic Atrophy (GA) Clinical Trial

Retrieved on: 
星期一, 四月 29, 2024
Health, Other Science, Clinical Trials, Research, Science, Optical, Biotechnology, AMD, Brain, University, Iron, Cell, Risk, Publication, Iron overload, Central nervous system, Inflammasome, K8, Disease, Nervous system, Patient, Eye, Multiple sclerosis, DSM-IV codes, ALS, Multimedia, Atrophy, Reactive oxygen species, Therapy, Ophthalmology, Science and nature, Pharmaceutical industry

Inflammasome Therapeutics ( https://www.inflam.com ), a private company developing a new class of inflammasome inhibitor drugs, Kamuvudines, as therapies for prevalent, degenerative diseases, announced the first patient has been dosed in a first-in-class clinical trial for dry AMD.

Key Points: 
  • Inflammasome Therapeutics ( https://www.inflam.com ), a private company developing a new class of inflammasome inhibitor drugs, Kamuvudines, as therapies for prevalent, degenerative diseases, announced the first patient has been dosed in a first-in-class clinical trial for dry AMD.
  • “This marks the second trial underway with our Kamuvudines in ophthalmology,” said Dr. Paul Ashton, President and CEO of Inflammasome Therapeutics, developers of both the compounds and delivery systems for administration.
  • There are 38 other interventional clinical trials for GA registered in clinicaltrials.gov., almost all of which target individual toxic substances, but not the underlying cause of the atrophy, inflammasome activation.
  • Inflammasome Therapeutics is expected to begin clinical trials in some of these diseases soon as well,” he affirmed.

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Retrieved on: 
星期三, 三月 13, 2024
Development, Gene editing, Growth, Regeneron Pharmaceuticals, Biotechnology, Science and nature, Merck Serono, Patient, Branches of microbiology, Acquisition, Virology, Executive Committee, Max Planck Society, CRISPR Therapeutics, University, Senior, Bayer, Publication, Therapy, Takeda, CRISPR, Amgen, CRSP, Medicine, Pharmaceutical industry

“We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics.

Key Points: 
  • “We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics.
  • Dr. Rommel currently serves as Executive Vice President, Global Head of Research & Development and a Member of the Executive Committee of Bayer Pharmaceuticals, Inc.
  • He joined Bayer from Roche, where he was most recently Senior Vice President, Global Head of Oncology, Pharma Research and Early Development (pRED).
  • He has authored more than 70 publications, including papers in Science and Nature, and is an inventor or co-inventor of 18 patents.

Inflammasome Therapeutics to Enter Clinic with Treatment for Dry AMD

Retrieved on: 
星期一, 十一月 13, 2023
Health, FDA, Surgery, General Health, Clinical Trials, Optical, Biotechnology, CNS, Eye, Iron, Human, Research, ALS, Science and nature, Therapy, Toxicity, Inflammasome, Retina, Disease, Risk, Clinical trial, Reactive oxygen species, Patient, Multimedia, Amyotrophy, Geographic atrophy, Multiple sclerosis, University, AMD, Aspirin, Central nervous system, Iron overload, Publication, Pharmaceutical industry, Medical device, Nature, Science

View the full release here: https://www.businesswire.com/news/home/20231113814506/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231113814506/en/
    inflammasome's sustained release implant contains the first of a new class of inflammasome inhibitor drugs, Kamuvudines, also developed by the company.
  • (Photo: Business Wire)
    In GA, the macula - the part of the retina responsible for central vision - slowly atrophies.
  • They only modestly slow the progression of the disease and increase the risk of developing wet AMD.
  • The start of the trial represents the next step in a decade-long research effort led by Inflammasome Therapeutics’ co-founder, Dr. Jayakrishna Ambati, initiated while he was at the University of Kentucky.

Nobody knows how consciousness works – but top researchers are fighting over which theories are really science

Retrieved on: 
星期三, 九月 27, 2023
Scientific study, Review, The New York Times, Economist, Consciousness, Research, Pseudoscience, Information theory, Science and nature, Patient, Association, The Economist, Coma, AI, Association for the Scientific Study of Consciousness, Letter, Pernicious, Information technology, Management, Retail, Risk management, Design, Tourism, Science, Nature

The science of consciousness is particularly hard, beset with philosophical difficulties and a scarcity of experimental data.

Key Points: 
  • The science of consciousness is particularly hard, beset with philosophical difficulties and a scarcity of experimental data.
  • And that might have been that, with researchers continuing to investigate these and other theories of how our brains generate experience.
  • The science of consciousness has its factions and quarrels but this development is unprecedented, and threatens to do lasting damage.

What is integrated information theory?

    • Italian neuroscientist Giulio Tononi first proposed integrated information theory in 2004, and it is now on “version 4.0”.
    • Roughly, this means the information the system as a whole has over and above the information had by its parts.
    • Instead, integrated information theory begins with “phenomenological axioms”, supposedly self-evident claims about the nature of consciousness.

Three criticisms

    • First, it argues this is not a “leading theory of consciousness” and has received more media attention than it deserves.
    • The third claim has provoked the most outcry: integrated information theory is “pseudoscience”.

Is integrated information theory a leading theory?

    • Whether you agree with integrated information theory or not – and I myself have criticised it – there is little doubt it is a “leading theory of consciousness”.
    • By one account, integrated information theory is the third-most discussed theory of consciousness in the scientific literature, out-stripped only by global workspace theory and recurrent processing theory.

Is it more problematic than other theories?

    • According to the letter, integrated information theory says “human fetuses at very early stages of development” are likely conscious.
    • Are the implications of integrated information theory more problematic than those of other leading theories?
    • That’s far from obvious, and there are certainly versions of other theories whose implications would be every bit as radical as those of integrated information theory.

Is it pseudoscience?

    • It also claims integrated information theory wasn’t “meaningfully tested” by the head-to-head contest earlier this year.
    • But none of this justifies treating integrated information theory – or indeed any other theory of consciousness – as pseudoscience.
    • In effect, it’s an attempt to “deplatform” or silence integrated information theory – to deny it deserves serious attention.

BioLumic announces Scientific Advisory Group

Retrieved on: 
星期一, 八月 16, 2021
Photobiology, Agriculture, Science and nature, King Abdullah University of Science and Technology, Organizational founder, University of Auckland, CSO, CEO, Cabot, DNA Plant Technology, Nutrition, Scientific Advisory Group for Emergencies, Seed, Plant Breeding Institute, Technology, Scientific Advisory Group, GLOBE, Botany, United States Air Force Scientific Advisory Board, Research, Doctor of Philosophy, DuPont, Biotechnology, Board, BASF Plant Science, Molecular biology, AG, Seedling, Plant, R&D, EMBO, Harvard Medical School, Genetics, Harvard University, Clarivate

NEW YORK and PALMERSTON NORTH, New Zealand, Aug. 16, 2021 (GLOBE NEWSWIRE) -- BioLumic Inc. (BioLumic), a biotechnology company that develops photomorphogenic light signals for agriculture, today announced the initial formation of a Scientific Advisory Board, composed of leading agricultural plant scientists.

Key Points: 
  • NEW YORK and PALMERSTON NORTH, New Zealand, Aug. 16, 2021 (GLOBE NEWSWIRE) -- BioLumic Inc. (BioLumic), a biotechnology company that develops photomorphogenic light signals for agriculture, today announced the initial formation of a Scientific Advisory Board, composed of leading agricultural plant scientists.
  • The Scientific Advisory Group will provide insights and guidance in the application of BioLumics photogenics platform to unravel novel and tractable science that will support commercial light signal applications.
  • BioLumic is an exciting agtech company with novel plant science to unlock said Professor Mark Tester, world-leading plant scientist.
  • The first members of the BioLumic Scientific Advisory Group are:
    John Bedbrook received a PhD in Molecular biology at Auckland University, was a Fulbright Fellow to Harvard Medical School, a Cabot Fellow to Harvard University and an EMBO fellow to The Plant Breeding Institute Cambridge England.